文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

耐多药结核分枝杆菌对非常规药物的敏感性及其与药代/药效参数的比较

Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究分析了217株耐多药结核分枝杆菌(含153株初治患者分离株和64株随访分离株),用刃天青微量稀释法测定9种非常规药物及异烟肼的MIC。结果显示多数药物对MDR菌株有体外活性,其中甲氧苄啶/磺胺甲噁唑、美罗培南/克拉维酸、利奈唑胺、氯法齐明和硝唑尼特与人药代/药效参数比较后具前景,值得进一步临床研究。

要点

  • 多数非常规药物对MDR结核分枝杆菌有体外抑菌活性。
  • 甲氧苄啶/磺胺甲噁唑、美罗培南/克拉维酸、利奈唑胺、氯法齐明和硝唑尼特具前景。
  • 既往治疗史未显示影响任何药物的敏感性。

核心结论

  • 多数非常规药物对MDR结核分枝杆菌显示出体外抑菌效果。
  • 将MIC与已发表的人体药代/药效参数比较后,甲氧苄啶/磺胺甲噁唑、美罗培南/克拉维酸、利奈唑胺、氯法齐明和硝唑尼特具前景,值得进一步临床研究。

研究设计与样本

  • 研究分析了217株MDR结核分枝杆菌分离株,包括153株来自不同患者的初始分离株和64株治疗过程中的随访分离株。
  • 采用刃天青微量稀释法测定甲氧苄啶/磺胺甲噁唑、甲氟喹、硫利达嗪、氯法齐明、阿莫西林/克拉维酸、美罗培南/克拉维酸、硝唑尼特、利奈唑胺和羟保泰松的MIC,并以异烟肼作为验证。
  • 计算MIC50和MIC90分别代表抑制50%和90%分离株生长的MIC。

主要发现

  • 初始分离株的MIC50(mg/L)分别为:甲氧苄啶/磺胺甲噁唑0.2/4、甲氟喹8、硫利达嗪4、氯法齐明0.25、阿莫西林/克拉维酸16/8、美罗培南/克拉维酸1/2.5、硝唑尼特16、利奈唑胺0.25、羟保泰松40。
  • 初始分离株的MIC90(mg/L)分别为:甲氧苄啶/磺胺甲噁唑0.4/8、甲氟喹8、硫利达嗪8、氯法齐明0.5、阿莫西林/克拉维酸32/16、美罗培南/克拉维酸8/2.5、硝唑尼特16、利奈唑胺0.25、羟保泰松60。
  • 异烟肼的MIC90>4 mg/L。
  • 没有证据表明既往治疗影响对任何药物的敏感性。

关键数值与推荐

  • 初始分离株甲氧苄啶/磺胺甲噁唑MIC50为0.2/4 mg/L、MIC90为0.4/8 mg/L。
  • 初始分离株美罗培南/克拉维酸MIC50为1/2.5 mg/L、MIC90为8/2.5 mg/L。
  • 初始分离株利奈唑胺MIC50和MIC90均为0.25 mg/L。
  • 初始分离株氯法齐明MIC50为0.25 mg/L、MIC90为0.5 mg/L。
  • 初始分离株硝唑尼特MIC50和MIC90均为16 mg/L。

临床怎么用

  • 甲氧苄啶/磺胺甲噁唑、美罗培南/克拉维酸、利奈唑胺、氯法齐明和硝唑尼特与人药代/药效参数比较后具前景,可考虑进一步临床研究。
  • 这些体外MIC数据可为评估非常规药物用于MDR-TB治疗的潜力提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The second-line drugs recommended to treat drug-resistant TB are toxic, expensive and difficult to procure. Given increasing resistance, the need for additional anti-TB drugs has become more urgent. But new drugs take time to develop and are expensive. Some commercially available drugs have reported anti-mycobacterial activity but are not routinely used because supporting laboratory and clinical evidence is sparse. METHODS: We analysed 217 MDR M. tuberculosis isolates including 153 initial isolates from unique patients and 64 isolates from follow-up specimens during the course of treatment. The resazurin microdilution assay was performed to determine MICs of trimethoprim/sulfamethoxazole, mefloquine, thioridazine, clofazimine, amoxicillin/clavulanate, meropenem/clavulanate, nitazoxanide, linezolid and oxyphenbutazone. Isoniazid was used for validation. We calculated the MIC 50 and MIC 90 as the MICs at which growth of 50% and 90% of isolates was inhibited, respectively. RESULTS: The MIC 50 s, in mg/L, for initial isolates were as follows: trimethoprim/sulfamethoxazole, 0.2/4; mefloquine, 8; thioridazine, 4; clofazimine, 0.25; amoxicillin/clavulanate, 16/8; meropenem/clavulanate, 1/2.5; nitazoxanide, 16; linezolid, 0.25; and oxyphenbutazone, 40. The MIC 90 s, in mg/L, for initial isolates were as follows: trimethoprim/sulfamethoxazole, 0.4/8; mefloquine, 8; thioridazine, 8; clofazimine, 0.5; amoxicillin/clavulanate, 32/16; meropenem/clavulanate, 8/2.5; nitazoxanide, 16; linezolid, 0.25; and oxyphenbutazone, 60. By comparison, the MIC 90 of isoniazid was >4 mg/L, as expected. There was no evidence that previous treatment affected susceptibility to any drug. CONCLUSIONS: Most drugs demonstrated efficacy against M. tuberculosis . When these MICs are compared with the published pharmacokinetic/pharmacodynamic profiles of the respective drugs in humans, trimethoprim/sulfamethoxazole, meropenem/clavulanate, linezolid, clofazimine and nitazoxanide appear promising and warrant further clinical investigation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cavanaugh JS, Jou R, Wu MH, et al. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters. J Antimicrob Chemother. 2017. PMID: 28333192. doi:10.1093/jac/dkx022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。